All In Biotech

Drug Trial Radar · NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

A Clinical Trial Comparing Treatment With Cangrelor (in Combination With Usual Care) to Usual Care, in Subjects Who Require Percutaneous Coronary Intervention (PCI).

Last checked: Nov 20, 2026Latest source record: May 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 5,364 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

5,364

Actual

Start

Sep 2006

Primary completion

May 2009

Study completion Jun 2010

Sponsor

Lead sponsor
The Medicines CompanyIndustry
Sponsor type
Industry
First posted
Oct 6, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a composite of all-cause mortality, myocardial infarction (MI), and ischemia-driven revascularization (IDR).

Conditions

  • Atherosclerosis
  • Acute Coronary Syndrome (ACS)

Interventions

  • CangrelorDrug

    cangrelor bolus (30 mcg/kg) \& cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)

  • clopidogrelDrug

    clopidogrel capsules (600 mg) at end of PCI

  • Placebo bolus & placebo infusionDrug

    placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)

  • Placebo capsules - end of PCIDrug

    Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing

  • Placebo capsules - end of infusionDrug

    Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)Time frame: randomization through 48 hours post randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Innovis Health

    Fargo, North Dakota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.